Comparison of the Hypazotemic Effects of Erythropoietin and U-74389G on Urea Levels

Tsompos, Constantinos; Panoulis, Constantinos; Toutouzas, Konstantinos; Triantafyllou, Aggeliki; Zografos, George; Papalois, Apostolos; Tsarea, Kalliopi; Karamperi, Maria

doi:10.33309/2638-7670.010103

Cited by 2 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis of these ratios from the same experiment, for 27 other seric variables, provides comparable results [Table 4]. [52,53]…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Comparison of the Hypocalcemic Effects of Erythropoietin and U-74389G

Tsompos,

Panoulis,

Toutouzas

et al. 2019

Clin Res Hematol

View full text Add to dashboard Cite

Aim: This study calculated the effects on serum calcium (Ca) levels, after treatment with either of two drugs: The erythropoietin (Epo) and the antioxidant lazaroid (L) drug U-74389G. The calculation was based on the results of two preliminary studies, each one of which estimated the certain influence, after the respective drug usage in an induced ischemia-reperfusion animal experiment. Materials and Methods: The two main experimental endpoints at which the serum Ca levels were evaluated were the 60 th reperfusion min (for the Groups A, C, and E) and the 120 th reperfusion min (for the Groups B, D, and F). Especially, the Groups A and B were processed without drugs, Groups C and D after Epo administration, whereas Groups E and F after the L administration. Results: The first preliminary study of Epo presented a non-significant hypocalcemic effect by 0.34% ± 0.68% (P = 0.6095). However, the second preliminary study of U-74389G presented a non-significant hypercalcemic effect by 0.14% ± 0.66% (P = 0.8245). These two studies were coevaluated since they came from the same experimental setting. The outcome of the coevaluation was that L is 2.3623042-fold (2.3482723-2.3764196) more hypercalcemic than Epo (P = 0.0000). Conclusions: The antioxidant capacities of U-74389G ascribe 2.3623042-fold more hypercalcemic effects than Epo (P = 0.0000).

show abstract

“…A meta-analysis of these ratios from the same experiment, for 27 other seric variables, provides comparable results [Table 4]. [52,53]…”

Section: Discussionmentioning

confidence: 88%

“…A U-74389G/erythropoietin efficacies ratios meta-analysis on 27 hematologic variables (23 variables with balancing efficacies and four variables with opposite efficacies)[52,53] …”

mentioning

confidence: 99%

Comparison of the Hypocalcemic Effects of Erythropoietin and U-74389G

Tsompos,

Panoulis,

Toutouzas

et al. 2019

Clin Res Hematol

View full text Add to dashboard Cite

show abstract

“…A metaanalysis of these ratios from the same experiment, for 20 other seric variables, provides comparable results [Table 4]. [39,40]…”

Section: Discussionmentioning

confidence: 90%

“…A U-74389G/erythropoietin efficacy ratio meta-analysis on 20 hematologic variables (16 variables with balancing efficacies and 4 variables with opposite efficacies)[39,40] …”

mentioning

confidence: 99%

Comparison of the Hypertransferasemic Effects of Erythropoietin and U-74389G on Aspartate Aminotransferase Levels

Tsompos,

Panoulis,

Toutouzas

et al. 2018

Clin Res Hematol

View full text Add to dashboard Cite

Aim: This study calculated the effects on aspartate aminotransferase (AST) levels, after treatment with either of two drugs: The erythropoietin (Epo) and the antioxidant lazaroid (L) drug U-74389G. The calculation was based on the results of two preliminary studies, each one of which estimated the certain influence, after the respective drug usage in an induced ischemiareperfusion (IR) animal experiment. Materials and Methods: The two main experimental endpoints at which the serum AST levels were evaluated were the 60 th reperfusion min (for the Groups A, C, and E) and the 120 th reperfusion min (for the Groups B, D, and F). Especially, Groups A and B were processed without drugs, Groups C and D after Epo administration, whereas Groups E and F after the L administration. Results: The first preliminary study of Epo presented a significant hypertransferasemic effect by 19.73 ± 7.71% (P = 0.0119). The second preliminary study of U-74389G presented a nonsignificant hypertransferasemic effect by 16.23 ± 8.59% (P = 0.0583). These two studies were coevaluated since they came from the same experimental setting. The outcome of the coevaluation was that L is 0.8224656-fold (0.8211631-0.8237701) less hypertransferasemic than Epo (P = 0.0000). Conclusions: The antioxidant capacities of U-74389G ascribe 0.8224656-fold less hypertransferasemic effects than Epo (P = 0.0000).

show abstract

Comparison of the Hypazotemic Effects of Erythropoietin and U-74389G on Urea Levels

Cited by 2 publications

References 31 publications

Comparison of the Hypocalcemic Effects of Erythropoietin and U-74389G

Comparison of the Hypocalcemic Effects of Erythropoietin and U-74389G

Comparison of the Hypertransferasemic Effects of Erythropoietin and U-74389G on Aspartate Aminotransferase Levels

Contact Info

Product

Resources

About